#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K CURRENT REPORT

## PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 26, 2004

### **Neose Technologies, Inc.**

(Exact name of issuer as specified in charter)

**DELAWARE**(State or Other

Jurisdiction of Incorporation or Organization) 0-27718

(Commission file number)

13-3549286

(I.R.S. Employer Identification Number)

#### 102 Witmer Road, Horsham, Pennsylvania 19044

(Address of principal executive offices)

(215) 315-9000

(Registrant s telephone number, including area code)

#### Item 5 -Other Events.

On April 26, 2004, the Company issued a press release announcing that it has entered into an agreement with MacroGenics, Inc. to apply Neose s proprietary GlycoAdvance and GlycoPEGylation technologies to MacroGenics compounds, with the goal of improving the therapeutic properties of these proteins. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

#### Item 7 Financial Statements, Pro Forma Financial Information and Exhibits.

- (a) Financial Statements of Businesses Acquired: None
- (b) Pro Forma Financial Information: None
- (c) Exhibits: Reference is made to the Exhibit Index annexed hereto and made a part hereof.

#### **Signatures**

#### Edgar Filing: NEOSE TECHNOLOGIES INC - Form 8-K

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Date: April 26, 2004

By: /s/ C. Boyd Clarke

C. Boyd Clarke

President and Chief Executive Officer

Index to Exhibits

Exhibit No. Description

Exhibit 99.1 Press Release dated April 26, 2004